Streptococcal tonsillitis has been implicated in psoriasis; however, few population studies have examined its role in the pediatric population.
To investigate the association between tonsillitis and pediatric psoriasis.
Data from the Danish National Birth Cohort were obtained on parentally reported psoriasis by age 11 years and history of tonsillitis at ages 6 to 18 months, 10 to 11 years, and (from hospital patient registry data) 0 to 11 years. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) of pediatric psoriasis using logistic regression analyses.
In total, 35 188 offspring were eligible for analyses. Tonsillitis at 6 to 18 months was not associated with pediatric psoriasis (adjusted OR, 0.73; 95% CI, 0.47-1.14), nor was recent tonsillitis at ages 10 to 11 years (adjusted OR, 1.09; 95% CI, 0.81-1.47). However, recurrent tonsillitis between ages 10 to 11 was strongly associated with pediatric psoriasis (adjusted OR, 2.28; 95% CI, 1.17-4.48). Our results for streptococcal tonsillitis indicated a potential association (adjusted OR, 2.12; 95% CI, 0.86-5.17).
It was not possible to clarify the temporal relationship between tonsillitis and pediatric psoriasis.
Recurrent tonsillitis is of clinical relevance to pediatric psoriasis.Le texte complet de cet article est disponible en PDF.
Key words : birth cohort, cohort, cross-sectional, early-onset psoriasis, epidemiology, infections, pediatric psoriasis, pediatrics, public health, tonsillitis, throat infections, Streptococcus
Abbreviations used : BMIz, CI, DAG, DNBC, DNPR, ICD, OR, WHtR
| Funding sources: Supported by a grant from the LEO Foundation and the Danish Dermatological Society. LEO Foundation and the Danish Dermatological Society were not involved in any portion of the study design, data collection, data analysis, manuscript preparation, or review process, nor in the decision to submit the manuscript for publication.
| Disclosure: Dr Skov has been a paid speaker for AbbVie, Eli Lilly, Novartis, and LEO Pharma; has been a consultant or served on advisory boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Admirall, and Sanofi; has served as an investigator for AbbVie, Janssen Cilag, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Regeneron, and LEO Pharma; and received research and educational grants from Novartis, Sanofi, Janssen Cilag, and Leo Pharma. Dr Zachariae has been a paid speaker for AbbVie, Eli Lilly, Novartis, CSL, and LEO Pharma; has been a consultant or served on advisory boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, Admirall, and CSL; and has served as an investigator for AbbVie, Janssen Cilag, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Regeneron, Takeda, and LEO Pharma. Mr Groot and Drs Blegvad and Nybo Andersen have no conflicts of interest to declare.